Ulotaront
Sponsors
Otsuka Pharmaceutical Development And Commercialization Inc., Otsuka Pharmaceutical Development & Commercialization Inc.
Conditions
Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults.generalised anxiety disorder
Phase 2
A Phase 2/3, Multicenter, Randomized, Double blind, Placebo controlled Trial of the Safety and Efficacy of Flexible Doses of SEP 363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.
CompletedCTIS2022-500538-27-00
Start: 2023-03-30End: 2025-11-05Target: 256Updated: 2025-12-18
A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder
CompletedCTIS2022-502077-42-00
Start: 2023-09-14End: 2025-09-17Target: 255Updated: 2025-08-29